Ms. Zhao Yan visits industry partner BioMimetics Sympathies

2023.01.12

From January 10 to January 11, 2023, Ms. Zhao Yan, President of Bloomage Biotech, accompanied by Ding Ke, General Manager of Hainan subsidiary, visited BioMimetics Sympathies ("BMS"), our partner in Japan, and Rohto Pharmaceutical Co., Ltd. ("Rohto Pharma"), and had in-depth exchanges with Naoki Urushihata, CEO of BMS, and Kunio Yamada, President of Rohto respectively, on the promotion of regenerative medicine projects and market demand in China and Japan, and discussed the strategic cooperation in further fields.


In June 2022, Bloomage Biotech formally entered into strategic cooperation with Rohto Pharma and BMS, and established a joint venture company, Bloomage Houyuan, in July 2022 to conduct research and commercial operation in the field of regenerative medicine and cell culture medium. Cell culture medium has been known as the "chip power" of the global biomedical industry, and it is also a key consumable for scientific research in the fields of biology and medicine.

Bloomage Biotech has always taken science and technology as the foundation of enterprise development and has mastered many key core technologies in the industry, such as microbial fermentation, enzymatic degradation technology, cross-linking technology, etc. Ms. Zhao Yan said that Bloomage Biotech has entered into strategic cooperation with BMS and Rohto Pharma, which will further enrich the key core technology matrix of the company and enhance the core technology competitiveness of the regenerative medicine and cell culture medium industry.